In addition, DPP4 activity is also activated by pancreatic NEP36; thus NEP inhibitors may increase GLP‐1 and decrease DPP4 activity leading to improvement of insulin sensitivity and pancreatic β cell functions in humans as supported by recent studies showed that ARNI was effective in T2DM patients.14 Here, DPP4 is linked to type 2 diabetes mellitus.